Reading PBH? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PBH free→Reading PBH? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PBH free→NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-06-12
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, while management's recent track record has been steady and capital-friendly. Earnings quality is neutral, and risk is elevated, with the sector backdrop presenting a headwind. Peer multiples imply a price about 14% above where it trades (it looks cheap on this basis); the read is fair. The company is not currently profitable, so the valuation leans on sales- and cash-based methods. If PBH cuts guidance on the next call, that could have a meaningful negative impact. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 8 valuation methods, at three horizons. Current price $47.82. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $48 PBH trades at 11× p/e, below its 13× p/e peer median. Our $55 fair value sits above the price; high confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 14% below a flat-multiple fair value, in line with our forecast of about -4%. This describes what's priced in, not a forecast of the move.
Only weak execution quality, a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 1.35x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 50% for the rest of the cohort, n=2269).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.99 → $0.87 (-12.1% / 30d). 0 raised, 3 cut, 5 covering analysts.
0 upgrades, 1 downgrade / 30d, 1 maintained. 71% of analysts rate Buy.
Divergence: fundamentals are strong but estimates are being cut. Worth reading the recent material events.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$118.
How much price usually moves either way.
On a bad day, this stock has moved -$289.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,663.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-12
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Fixing the last earnings miss is important for gaining back investor trust.
Confirms:Q1 earnings show a big improvement from the last quarter.
Disproves:Earnings miss expectations again or show no improvement from the last quarter.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for PBH yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 13, 2026, the Company announced financial results for the fiscal quarter and year ended March 31, 2026. A copy of the press release announcing the Company's earnings results for the fiscal quarter and year ended March 31, 2026 is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
Trailing four: 2025-Q3, 2026-Q1, 2026-Q2, 2026-Q3
A side-by-side read on sector standing, valuation, and risk versus Pharmaceuticals.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
PBH Prestige Consumer Healthcare | Above typical Show detailsSector percentile: 77 of 100 | fair | elevated |
LLY Lilly (Eli) | Above typical Show detailsSector percentile: 85 of 100 | expensive | moderate |
JNJ Johnson & Johnson | Typical Show detailsSector percentile: 69 of 100 | expensive | low |
MRK Merck & Co. | Typical Show detailsSector percentile: 62 of 100 | expensive | moderate |
PFE Pfizer | Typical Show detailsSector percentile: 62 of 100 | fair | low |
1 material management or governance event in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
Not investment advice. As of 2026-06-12.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
The company aims to grow by acquiring other businesses, as evidenced by recent acquisition announcements.
The company is focused on enhancing its operating income through various initiatives.
The company is working to address the recent earnings miss and improve financial performance.
Why it matters: This will show if the company can address the recent earnings miss. Investors will focus on any recovery in operating income.
Confirms one read:Earnings per share are better than expected. This shows signs of recovery.
Confirms the other:Earnings per share falls short of expectations, confirming ongoing issues.
Why it matters: If operating income keeps falling, it may show bigger profit problems. This can hurt investor trust.
Confirms:Operating income is below $75.5M in the next quarter.
Disproves:Operating income is above $75.5M in the next quarter.
Why it matters: This acquisition could boost growth and show management's commitment to expansion. Investors will look for signs of how this affects revenue.
Confirms:Look for positive revenue growth in the next quarter after the acquisition.
Disproves:Revenue growth fails to improve or declines in the next quarter after the acquisition.
Entry into a Material Definitive Agreement. On May 10, 2026, PBH Australia Holding Company Pty Limited (“Purchaser”), an Australian company and a wholly owned indirect subsidiary of Prestige Consumer Healthcare Inc. (the “Company”), and Care Pharmaceuticals Pty Limited (“Care”), an Australian company and a wholly owned indirect subsidiary of the Company, entered into a definitive agreement (the “Sale and Purchase Deed”) with Tailor Investments Pty Limited and Standive Pty Limited, both Austra…